Editorial
Allosterically targeting EGFR drug-resistance gatekeeper mutations
Abstract
Lung cancer is by far the leading cause of cancer-related death with nearly 1.7 million deaths worldwide in 2016. The most common type of lung cancer is non-small cell lung cancer (NSCLC) accounting for 80% of lung cancer cases.